ABSTRACT
Clopress; Placil Indications: Obsessive-compulsive disorder Category: Tricyclic antidepressant Half-life: 21-31 hours Clinically important, potentially hazardous interactions with: amprenavir,
arbutamine, clonidine, epinephrine, formoterol, guanethidine, isocarboxazid, linezolid, MAO inhibitors, phenelzine, quinolones, sparfloxacin, tranylcypromine
Reactions
Skin Acne (2%)
Allergic reactions (sic) (<3%) Cellulitis (2%) Cheilitis Chloasma Dermatitis (sic) (2%) (1991): Ljunggren B+, Contact Dermatitis 24, 259 Diaphoresis (29%) (1992): Guelfi JD+, Br J Psychiatry 160, 519 (1990): McTavish D+, Drugs 38, 19 (43%) Edema (2%) Erythema Exanthems Flushing (8%) Folliculitis Photosensitivity (<1%) (1991): Ljunggren B+, Contact Dermatitis 24, 259 (1989): Tunca Z+, Am J Psychiatry 146, 552 (1979): Parkes JD+, Lancet 2, 1085 Pigmentation (pseudocyanotic) (1989): Tunca Z+, Am J Psychiatry 146, 552 Pruritus (6%) Psoriasis Purpura (3%) Pustules
Rash (sic) (8%) Seborrhea Urticaria (1%) Vasculitis Xerosis (2%)
Hair Hair-alopecia (<1%)
Hair-alopecia areata (1993): Kubota T+, Acta Neurol Napoli (Italian) 15, 200 Hair-hypertrichosis
Other Ageusia
Black tongue Dysgeusia (8%) Galactorrhea (<1%) Gingivitis Glossitis Gynecomastia (2%) Headache Mastodynia (1%) Myalgia (13%) Paresthesias Sialorrhea Stomatitis Tongue ulceration Vaginitis (2%) Xerostomia (84%) (1992): Cohen DJ+, Psychiatr Clin North Am 15, 109 (1992): DeVeaugh-Geiss J+, J Am Acad Child Adolesc Psychiatry 31, 45 (1992): Guelfi JD+, Br J Psychiatry 160, 519 (1990): McTavish D+, Drugs 38, 19
Trade name: Klonopin (Roche) Other common trade names: Clonex; Iktorivil; Landsen; Lonazep; Rivotril Indications: Petit mal and myoclonic seizures Category: Benzodiazepine anticonvulsant Half-life: 18-50 hours Clinically important, potentially hazardous interactions with: amprenavir,
chlorpheniramine, clarithromycin, efavirenz, esomeprazole, imatinib, indinavir, nelfinavir
Reactions
Skin Allergic reactions (sic) (1-10%)
Angioedema (1976): Pinder RM+, Drugs 12, 321 Ankle edema Dermatitis (sic) (1-10%) Diaphoresis (>10%) Erythema multiforme (1998): Amichai B+, Clin Exp Dermatology 23, 206 Exanthems (1976): Pinder RM+, Drugs 12, 321 Facial edema Hypermelanosis (1976): Pinder RM+, Drugs 12, 321 Pruritus Pseudo-mycosis fungoides (1996): Gordon KB+, J Am Acad Dermatol 34, 304 Purpura (1976): Pinder RM+, Drugs 12, 321 Rash (sic) (>10%) Urticaria
Hair Hair-alopecia
(2000): Mercke Y+, Ann Clin Psychiatry 12, 35 Hair-hirsutism
Other Black tongue
(2000): Heymann WR, Cutis 66, 25 Burning mouth syndrome (2001): Culhane NS+, Ann Pharmacother 35(7), 874 Dysgeusia (2000): Heymann WR, Cutis 66, 25 Gingivitis Headache Injection-site phlebitis Injection-site thrombosis Oral mucosal eruption (1986): Bernard K, Lijec Vjesn (Serbo-Croatian-Roman) 108, 235 Oral ulceration
Paresthesias Pseudolymphoma (1995): Magro CM+, J Am Acad Dermatol 32, 419 (1988): Kardaun SH+, Br J Dermatol 118(4), 545 Sialopenia (>10%) Sialorrhea (1-10%) Xerostomia (>10%) (2000): Heymann WR, Cutis 66, 25
Trade names: Catapres (Boehringer Ingelheim); Combipres (Boehringer Ingelheim) Other common trade names: Barclyd; Catapresan; Daipres; Dixarit; Duraclon;
Haemiton; Nu-Clonidine; Sulmidine Indications: Hypertension Category: Alpha-2-adrenoceptor blocker; Antihypertensive Half-life: 6-24 hours Clinically important, potentially hazardous interactions with: acebutolol,
amitriptyline, amoxapine, atenolol, betaxolol, carteolol, clomipramine, desipramine, doxepin, esmolol, imipramine, metoprolol, nadolol, nortriptyline, penbutolol, pindolol, propranolol, protriptyline, timolol, tricyclic antidepressants, trimipramine, verapamil
Combipres is clonidine and chlorthalidone
Reactions
Skin Angioedema (<1%)
(1995): Waldfahrer F+, HNO (German) 43, 35 Depigmentation (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 (1995): Doe N+, Arch Intern Med 155, 2129 (from patch) Dermatitis (from patch) (20%) (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 (1999): Polster AM+, Cutis 63, 154 (1997): Shelley ED+, J Geriatr Dermatol 4, 192 (1995): Corazza M+, Contact Dermatitis 32, 246 (1994): Tom GR+, Ann Pharmacother 28, 889 (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
226 (passim) (1991): Ito MK+, Am J Med 91, 42S (1991): McChesney JA, West J Med 154, 736
(1990): Hogan DJ+, J Am Acad Dermatol 22, 811 (1990): Scheper RJ+, Contact Dermatitis 23, 81 (1989): Fillingim JM+, Clin Ther 11, 398 (1989): Holdiness MR, Contact Dermatitis 20, 3 (1988): Horning JR+, Chest 93, 941 (1987): Bigby M+ , JAMA 258, 1819 (letter) (1987): Maibach HI, Contact Dermatitis 16, 1 (1986): Hollifield J, Am Heart J 112, 900 (1986): Weber MA, Am Heart J 112, 906 (1986): White TM+, West J Med 145, 104 (1985): Grattan CEH+, Contact Dermatitis 2, 225 (1985): Maibach H, Contact Dermatitis 12, 192 (1984): van Ketel WG, Ned Tijdschr Geneeskd (Dutch) 128, 34 (1983): Boekhorst JC, Lancet 2, 1031 (1983): Groth H+, Lancet 2, 850 Diaphoresis (1990): Leeman CP, J Clin Psychiatry 51, 258 Eczema (sic) (1987): Dick JBC+, Lancet 1, 516 (1985): Grattan CEH+, Contact Dermatitis 12, 225 Edema Erythema (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 (1987): Dick JBC+, Lancet 1, 516 Exanthems Excoriations (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 Herpes simplex (1987): Wiser TH+, J Am Acad Dermatol 17, 143 Irritation (from patch) (1999): Dias VC+, Am J Ther 6, 19 Lupus erythematosus (1994): Heilmann G+, Dtsch Med Wochenschr (German) 119, 858 (1994): Yung RL+, Rheum Dis Clin North Am 20, 61 (1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford,
226 (passim) (1981): Witman G+, R I Med J 64, 147 Pemphigus (anogenital and cicatricial) (1980): van Joost T+, Br J Dermatol 102, 715 Peripheral edema Pigmentation (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 (1987): Wiser TH+, J Am Acad Dermatol 17, 143 (from patch) Pityriasis rosea (1998): Reed BR, Denver, CO (2 cases-in siblings) (from Internet) (observation)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin Blackwell, Oxford, 226 (passim)
Pruritus (>5%) (1999): Dias VC+, Am J Ther 6, 19 (1987): Dick JBC+, Lancet 1, 516 (1984): Weber MA+, Arch Intern Med 144, 1211 (1984): Weber MA+, Lancet 1, 9 (1983): Boekhorst JC, Lancet 2, 1031 Psoriasis (1981): Wilkin J, Arch Dermatol 117, 4 Rash (sic) (1-10%) (1988): Glassman AH, JAMA 259, 2863 Raynaud’s phenomenon (<1%) Scaling (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 Ulcerations (1-10%) Urticaria (<1%) Vesiculation (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136
Hair Hair-alopecia (<1%)
Other Acute intermittent porphyria
Application-site vesicles (1987): Dick JBC+, Lancet 1, 516 Dysgeusia (from patch) Gynecomastia (<1%) Headache Hyperesthesia (1-10%) Immune complex disease (1989): Petersen HH+, Acta Derm Venereol (Stockh) 69, 519 Induration (2002): Prisant LM, J Clin Hypertens (Greenwich) 4(2), 136 Pseudolymphoma (1997): Shelley WB+, Lancet 350, 1223 (at site of patch) Xerostomia (40%) (2000): Geyer O+, Graefes Arch Clin Exp Ophthalmol 238, 149 (2000): Litt JZ, Beachwood, OH (personal case) (observation) (1999): Dias VC+, Am J Ther 6, 19 (1988): Glassman AH, JAMA 259, 2863 (1984): Weber MA+, Arch Intern Med 144, 1211 (1984): Weber MA+, Lancet 1, 9 (1983): Boekhorst JC, Lancet 2, 1031
